Mauna Kea Technologies Reports Preliminary Fourth Quarter 2020 Sales
U.S. Sales up 34% to 38% year-over-year and up 20% to 23% quarter-over-quarter.
Regulatory News:
Mauna Kea Technologies
(Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced preliminary sales for the fourth quarter of 2020. Given the significant uncertainties associated with pace of recovery from the COVID-19 pandemic, the Company has elected to provide, in this context, specific information on expected revenue trends for the fourth quarter of 2020. Preliminary sales figures for the fourth quarter of 2020 are unaudited.
Preliminary Sales Summary for Fourth Quarter 2020 (Unaudited figures)